Literature DB >> 9406657

Evidence for direct interaction of ketamine with alpha 1- and beta 2-adrenoceptors.

R K Bevan1, M A Rose, K A Duggan.   

Abstract

1. Ketamine has a number of effects that suggest that it may interact with alpha- and beta-adrenoceptors. To date, the experimental evidence for this has been indirect and has been based on physiological studies using competitive blocking agents. In the present study we sought to determine from receptor binding studies whether ketamine binds directly to alpha- and beta-adrenoceptors. 2. Membrane preparations of alpha 1- and beta 2-adrenergic binding sites were obtained from urinary bladder and urethrae of sheep. These binding sites were characterized by saturation analyses using [3H]-prazosin for alpha 1-adrenoceptor binding sites and [125I]-cyanopindolol (CYP) for the beta 2-adrenoceptor binding sites. The receptors were further characterized by displacement studies using selective and non-selective antagonists. 3. Studies in which ketamine was used to displace [3H]-prazosin revealed a Kd of 3.40 +/- 1.23 x 10(-3) mol/L for ketamine binding to alpha 1-adrenoceptors. Displacement studies of [125I]-CYP by ketamine showed a Kd of 0.35 +/- 0.03 x 10(-3) mol/L for ketamine binding to beta 2-adrenoceptors. 4. We conclude that ketamine interacts directly with both alpha 1- and beta 2-adrenoceptors and that such interactions probably explain the reported effects of this agent on the vasculature and the bronchial tree.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406657     DOI: 10.1111/j.1440-1681.1997.tb02720.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  9 in total

Review 1.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 2.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

Review 3.  Ketamine: review of its pharmacology and its use in pediatric anesthesia.

Authors:  S A Bergman
Journal:  Anesth Prog       Date:  1999

Review 4.  Non-pharmacological factors that determine drug use and addiction.

Authors:  Serge H Ahmed; Aldo Badiani; Klaus A Miczek; Christian P Müller
Journal:  Neurosci Biobehav Rev       Date:  2018-09-01       Impact factor: 8.989

5.  Commonly used intravenous anesthetics decrease bladder contractility: An in vitro study of the effects of propofol, ketamine, and midazolam on the rat bladder.

Authors:  Canan Ceran; Arzu Pampal; Ozgur Goktas; H Kutluk Pampal; Ercument Olmez
Journal:  Indian J Urol       Date:  2010-07

6.  Intravital Microscopy for the Study of Hepatic Glucose Uptake.

Authors:  Megan L Stefkovich; Sun Woo Sophie Kang; Natalie Porat-Shliom
Journal:  Curr Protoc       Date:  2021-05

7.  Ketamine Metabolite (2R,6R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors.

Authors:  Thomas T Joseph; Weiming Bu; Wenzhen Lin; Lioudmila Zoubak; Alexei Yeliseev; Renyu Liu; Roderic G Eckenhoff; Grace Brannigan
Journal:  ACS Chem Neurosci       Date:  2021-04-27       Impact factor: 4.418

8.  The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use.

Authors:  Sarbjeet S Kalsi; David M Wood; Paul I Dargan
Journal:  Emerg Health Threats J       Date:  2011-04-15

9.  Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997-2019.

Authors:  John Martin Corkery; Wan-Chu Hung; Hugh Claridge; Christine Goodair; Caroline S Copeland; Fabrizio Schifano
Journal:  J Psychopharmacol       Date:  2021-06-05       Impact factor: 4.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.